Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorGaize
About this trial
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged between 18 and 65, having given written informed consent to participate in the research trial.
Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
Normal or corrected to normal vision using either glasses or contact lenses, or surgery.
Disqualifiers
Enrolled in, or participated in another clinical trial within 30 days before the study
Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.
Had your eyes dilated by a medical doctor in the previous 24 hours.
Photosensitive epilepsy
Trial population
Participant population is limited to the city of Philadelphia, PA
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Prescription Psychotropic Medications
DrugCurrently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
Treatment groups
50 Participants
are divided into 2 treatment groupsGroup A: Experimental Group1 intervention
Group B: Control Group1 intervention
Trial outcomes
Primary outcomes
1
Collection of Ophthalmic Data
Accuracy of the Gaize device in detecting eye-movement metrics consistent with prescribed psychotropic medication use, as determined by Drug Recognition Expert (DRE) testing protocols in a controlled virtual environment.
Time frame
1 Day Source ClinicalTrials.gov